New Drugs in Oncology

June 1 from 11:00 AM-5:00 PM and June 2 from 7:30 AM-11:00 AM

Seminar Description

The New Drugs in Oncology Seminar will focus on the theoretical and practical aspects of both recently approved drugs and those on their way to approval. Topics covered will include mechanisms of action, administration, toxicity and side-effect management, and use in the clinic.  

Seminar Committee

View Seminar Committee Disclosures

George W. Sledge, MD, FASCO​ (Co-Chair)​
Stanford University Medical Center

Anthony W. Tolcher, MD (Co-Chair)​
The START Center for Cancer Care

Howard A. Burris, MD, FASCO​
Sarah Cannon Research Institute

Bruce E. Hillner, MD, FASCO
Virginia Commonwealth University

Shivaani Kummar, MD, FACP
Stanford University Medical Center

Patricia LoRusso, DO
Yale University

Richard Pazdur, MD
U.S. Food and Drug Administration

Lee S. Rosen, MD
UCLA Santa Monica Hematology-Oncology

Howard McLeod, PharmD
H. Lee Moffitt Cancer Center and Research Institute

Seminar Agenda

Day 1: Thursday, June 1, 2017: 12:30 PM – 5:00 PM

12:30 PM – 1:00 PM Lunch
1:00 PM – 2:20 PM

Session 1: Basket Trials as a New Model for Drug Development: A Discussion

 

Shivaani Kummar, MD, FACP - Chair/Moderator
Stanford University School of Medicine

 

Keith Flaherty, MD
Massachusetts General Hospital
Basket Trials as a New Model for Drug Development - Point

 

Patricia LoRusso, DO
Yale Cancer Center, Yale University
Basket Trials as a New Model for Drug Development - Counterpoint

 

Stanley Hamilton, MD
The University of Texas MD Anderson Cancer Center
Practical Challenges and the Direction the Field is Going

 

Panel Question and Answer

 

2:20 PM – 2:35 PM

Session 2: Assessing the Value of the NCI Cancer Therapy Evaluation Program (CTEP)

 

TBD - Chair/Moderator

 

TBD
Assessing the Value of the NCI Cancer Therapy Evaluation Program​ - Point

 

Geoffrey Shapiro, MD, PhD
Dana-Farber Cancer Institute
Assessing the Value of the NCI Cancer Therapy Evaluation Program​ - Point

 

Anthony Tolcher, MD
START
Assessing the Value of the NCI Cancer Therapy Evaluation Program​ - Counterpoint

 

Panel Question and Answer

 

3:45 PM – 5:00 PM

Session 3: Combination Therapies

 

Bruce Hillner, MD - Chair
Virginia Commonwealth University

 

TBD
Taking the Pulse of Immunotherapy: Current Status and Future Possibilities

 

TBD
Evaluation of Immunotherapy and Novel Combinations in Oncology

 

TBD
Identifying Appropriate Endpoints for Combination Therapy Trials

 

Panel Question and Answer

 

Day 2: Friday, June 2, 2017: 7:00 AM – 11:00 AM

7:00 AM – 11:00 AM

Session 4: New Drugs in Oncology & Incorporation into the Clinic 

Session Agenda Currently Being Finalized